Supernus Pharmaceuticals reported $170.05M in Sales Revenues for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbott ABT:US $ 11257M 638M
Aerie Pharmaceuticals AERI:US $ 33.31M 3.48M
Ani Pharmaceuticals ANIP:US $ 73.86M 9.38M
Aurora Cannabis Inc ACB:CN 50.43M 10.15M
Bristol Myers Squibb BMY:US $ 11887M 239M
Canopy Growth Corp WEED:CN C$ 110.12M 1.66M
Cara Therapeutics CARA:US $ 23M 18.21M
Corcept Therapeutics CORT:US $ 103.39M 9.7M
Eisai 4523:JP Y 184262M 6639M
Eli Lilly And LLY:US $ 6488M 1322M
Endo International Ordinary Shares ENDP:US $ 569.11M 83.14M
Horizon Pharma HZNP:US $ 876.41M 8.83M
JAZZ PHA JAZZ:US $ 932.88M 119.16M
Lannett LCI:US $ 78.36M 8.15M
Marinus Pharmaceuticals MRNS:US 1.79M 12.4M
Pacira Pharmaceuticals PCRX:US $ 169.41M 11.42M
Perrigo Ordinary Shares PRGO:US $ 1121.7M 47.2M
Pfizer PFE:US $ 27742M 2081M
Revance Therapeutics RVNC:US $ 28.37M 3.11M
Supernus Pharmaceuticals SUPN:US $ 170.05M 17.55M
Teva Pharmaceutical Industries TEVA:US $ 3786M 125M
United Therapeutics UTHR:US $ 466.9M 5M
Xeris Pharmaceuticals Inc XERS:US $ 25.31M 3.23M